ISOPAQUE 440 Drug Patent Profile
✉ Email this page to a colleague
When do Isopaque 440 patents expire, and what generic alternatives are available?
Isopaque 440 is a drug marketed by Ge Healthcare and is included in one NDA.
The generic ingredient in ISOPAQUE 440 is calcium metrizoate; meglumine metrizoate; metrizoate magnesium; metrizoate sodium. There are two hundred and eighty-two drug master file entries for this compound. Additional details are available on the calcium metrizoate; meglumine metrizoate; metrizoate magnesium; metrizoate sodium profile page.
Summary for ISOPAQUE 440
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 70 |
Patent Applications: | 1,730 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ISOPAQUE 440 at DailyMed |
US Patents and Regulatory Information for ISOPAQUE 440
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ge Healthcare | ISOPAQUE 440 | calcium metrizoate; meglumine metrizoate; metrizoate magnesium; metrizoate sodium | INJECTABLE;INJECTION | 016847-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ISOPAQUE 440
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Ge Healthcare | ISOPAQUE 440 | calcium metrizoate; meglumine metrizoate; metrizoate magnesium; metrizoate sodium | INJECTABLE;INJECTION | 016847-001 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ISOPAQUE 440
See the table below for patents covering ISOPAQUE 440 around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
United Kingdom | 973881 | ⤷ Try a Trial | |
Denmark | 125282 | ⤷ Try a Trial | |
France | 1548251 | ⤷ Try a Trial | |
Spain | 271951 | ⤷ Try a Trial | |
Germany | 1518051 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ISOPAQUE 440
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2365988 | CA 2018 00006 | Denmark | ⤷ Try a Trial | PRODUCT NAME: PATIROMER SORBITEX CALCIUM AND ANY SALTS AND DERIVATIVES THEREOF; REG. NO/DATE: EU/1/17/1179/001-009 20170721 |
0933372 | SPC/GB08/018 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: FOSAMPRENAVIR CALCIUM: ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-1-(PHENYLMETHYL)-2(PHOSPHONOOXY)PROPYL)-CARBABAMIC ACID C-((3S)-TETRAHYDRO-3-FURANYL) ESTER CALCIUM SALT; REGISTERED: UK EU/1/04/282/001 20040712; UK EU/1/04/282/002 20040712 |
0720599 | 300689 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ATORVASTATINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ATORVASTATINE CALCIUM TRIHYDRATE; NATIONAL REGISTRATION NO/DATE: RVG114373-114376 20141027; FIRST REGISTRATION: FR 2014091200122 20140912 |
2957286 | 300962 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: PATIROMER SORBITEX CALCIUM; REGISTRATION NO/DATE: EU/1/17/1179 20170721 |
0933372 | 13/2008 | Austria | ⤷ Try a Trial | PRODUCT NAME: FOSAMPRENAVIR ALS FOSAMPRENAVIR-CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001 - EU/1/04/282/002 (MITTEILUNG VOM 14.07.2004) 20040713 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |